For Graves disease refractory to antithyroid medications, what is the role of selective thyroid artery embolisation?

Thyroid Artery Embolization for Refractory Graves Disease

Thyroid artery embolization (TAE) should NOT be used as a routine treatment for Graves disease refractory to antithyroid medications; instead, proceed directly to radioactive iodine ablation or thyroidectomy, which remain the established definitive therapies with superior safety profiles and efficacy. 1, 2

Standard Treatment Pathway for Refractory Graves Disease

When antithyroid medications fail or are not tolerated, the evidence-based approach is:

First-Line Definitive Therapy Options

Radioactive Iodine (RAI) Ablation:

• Achieves 82.5% remission rates with only 7.1% relapse in Graves disease 3
• Represents the preferred definitive therapy when antithyroid drugs fail 1
• Critical caveat: If moderate-to-severe thyroid eye disease (TED) is present, RAI should be avoided or used with extreme caution and mandatory steroid prophylaxis (short course of low-dose prednisone) 4
• In mild TED with recent onset or risk factors for progression, steroid prophylaxis is strongly recommended if RAI is selected 4

Thyroidectomy:

• Achieves 100% remission with no relapse 3
• Should be the preferred option when RAI is contraindicated 3
• Particularly indicated in moderate-to-severe active TED where RAI is generally avoided 4
• Represents a valid option alongside antithyroid drugs in patients with significant TED 4

Why TAE Is Not Recommended

Limited and Concerning Evidence

Lack of robust safety data:

• The 2025 systematic review explicitly states that "significant risk of serious complications (including nontarget embolization and mortality)" precludes recommending TAE as routine treatment 2
• No standardized, safe protocol exists 2
• Serious risks include nontarget embolization and documented mortality 2

Inferior to established therapies:

• Current established therapies (RAI and surgery) have "high efficacy and lower complication rates" compared to TAE 2
• While older studies reported 63.6-78.6% euthyroid rates with TAE 5, 6, these lack long-term safety data and comparison to standard treatments

Absence from clinical guidelines:

• TAE is not mentioned in any major endocrine society guidelines for Graves disease management 1
• Guidelines consistently recommend antithyroid drugs, RAI, or surgery as the only acceptable treatment modalities 1

Exceptional Circumstances Only

TAE should only be considered when:

• Standard treatments (antithyroid drugs, RAI, and surgery) have ALL failed or are contraindicated 2
• The procedure is performed at specialized centers with extensive embolization expertise 2
• The patient has been fully counseled on the experimental nature and serious risks including mortality 2

Example scenario: A neutropenic patient with thyroid storm where surgery risks infection and antithyroid drugs caused the neutropenia 7

Practical Algorithm for Refractory Graves Disease

1. Confirm true refractoriness: Ensure adequate trial of antithyroid drugs (methimazole or propylthiouracil) with appropriate dosing 1

2. Assess for thyroid eye disease: Perform ophthalmologic evaluation to grade TED severity and activity 4

3. Select definitive therapy based on TED status:

   • No TED or mild inactive TED: RAI ablation is preferred 4
   • Mild active TED with risk factors: RAI with mandatory steroid prophylaxis 4
   • Moderate-to-severe active TED: Thyroidectomy is preferred; avoid RAI 4
   • Moderate-to-severe inactive TED: Either RAI (with steroid prophylaxis if risk factors present) or thyroidectomy 4

4. Reserve TAE only for: Patients who cannot undergo RAI or surgery due to absolute contraindications, and only at expert centers 2